Screener
Travere Therapeutics, Inc. TVTX Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:45 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001438533-26-000042
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Basic and diluted: | ||
| Net loss per common share | $(0.40) | $(0.47) |
| Weighted average common shares outstanding | 91,868,862 | 88,355,973 |
| Comprehensive loss: | ||
| Net loss | $(37,102) | $(41,226) |
| Foreign currency translation gain (loss) | 447 | (686) |
| Unrealized loss on marketable debt securities | (320) | (77) |
| Comprehensive loss | $(36,975) | $(41,989) |
Item 1. Financial Statements
FAQ
- What is Travere Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
- Travere Therapeutics, Inc. (TVTX) reported comprehensive income (loss), net of tax, attributable to parent of -$36.98M in Q1 2026.
- How has Travere Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- Travere Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent increased by 11.9% year-over-year, from -$41.99M to -$36.98M.
- What is the long-term trend for Travere Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
- Over 4 years (2021 to 2025), Travere Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent has grown at a -36.5% compound annual growth rate (CAGR), from -$179.75M to -$29.25M.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- This metric captures changes in equity resulting from non-owner sources that are not included in traditional net income, such as unrealized gains or losses on financial instruments or foreign currency translation adjustments. It provides a more holistic view of the company's financial health by accounting for volatility in assets and liabilities that do not flow through the standard income statement. Tracking this figure helps investors understand the broader impact of market fluctuations on the company's total equity position.
Ask your AI about Travere Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude